NCT06503250View on ClinicalTrials.gov

A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

CompletedOBSERVATIONAL
Enrollment

113

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

November 27, 2024

Study Completion Date

November 27, 2024

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
DRUG

Atezolizumab

Observational Study

DRUG

Bevacizumab

Observational Study

RADIATION

Transarterial Chemoembolization

Observational Study

Trial Locations (5)

200032

Zhongshan Hospital Fudan University, Shanghai

510080

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

510630

The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou

710061

The First Affiliated Hospital of Xian Jiao Tong University, Xi'an

DUMMY_VALUE

Tianjin First Central Hospital, Tianjin

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT06503250 - A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization | Biotech Hunter | Biotech Hunter